Clinical Trials in the USA / NCT07845071
Recruiting
Phase 3
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
NCT07845071 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Pain
Investigational drug(s) / intervention(s)
Cebranopadol 400 ug: Participants receive Cebranopadol 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.
Study summary
The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.
Eligibility
Inclusion Criteria:
* Adults 18 to 75 years of age.
* Able to provide informed consent.
* Experiencing moderate to severe acute pain related to: 1) An ambulatory surgical procedure expected to cause pain lasting at least 72 hours, or 2) A traumatic or non-traumatic musculoskeletal condition.
* Have a pain score of at least 4 on a 0 to 10 pain rating scale before starting study treatment.
* Willing and able to comply with study requirements
Exclusion Criteria:
* Chronic pain condition that requires ongoing pain medication.
* Significant medical or psychiatric condition that could affect participation or study results.
* History of substance use disorder or misuse of alcohol or drugs.
* Current use of medications that may interfere with the study drug or pain assessments.
* Known allergy or intolerance to cebranopadol or permitted rescue pain medications.
* Pregnant or breastfeeding.
* Participation in another clinical trial or receipt of an investigational drug within the protocol-defined period before study entry.
* Any condition that, in the investigator's opinion, would make participation unsafe or interfere with study assessments.
Primary outcome measure(s)
- Sum of pain intensity differences through 48 hours (SPID48) — From 0 through 48 hours
Sum of pain intensity differences through 48 hours (SPID48), calculated from NPRS assessments collected following the first administration of cebranopadol.
Trial sites (15)
| Facility | City | Region | Status |
|---|---|---|---|
| Adneuris Site 001115 | Phoenix | Arizona | Recruiting |
| Adneuris Site 001118 | Riverside | California | Recruiting |
| Adneuris Site 001119 | Longmont | Colorado | Recruiting |
| Adneuris Site 001122 | Savannah | Georgia | Recruiting |
| Adneuris Site 001123 | O'Fallon | Illinois | Recruiting |
| Adneuris Site 001125 | Annapolis | Maryland | Recruiting |
| Adneuris Site 001120 | Oradell | New Jersey | Recruiting |
| Adneuris Site 001124 | Tulsa | Oklahoma | Recruiting |
| Adneuris Site 001110 | Bellaire | Texas | Recruiting |
| Adneuris Site 001117 | Forney | Texas | Recruiting |
| Adneuris Site 001104 | McAllen | Texas | Recruiting |
| Adneuris Site 001116 | Plano | Texas | Recruiting |
| Adneuris Site 001111 | San Antonio | Texas | Recruiting |
| Adneuris Site 001121 | San Antonio | Texas | Recruiting |
| Adneuris Site 001101 | Salt Lake City | Utah | Recruiting |
More Adneuris Therapeutics, Inc. trials in the USA
Other trials for the same condition
RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS)
Active, not recruiting
Pivotal Study on the NOVABLOC System for Patients Undergoing Primary Total Knee Arthroplasty
Active, not recruiting
Phase 1 Study of SBS-147 in Healthy Adults
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07845071 on ClinicalTrials.gov ↗ ← All trials in the USA